First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

被引:0
作者
Ang, J. E. [1 ]
Hauns, B. [2 ]
Mais, A. [2 ]
Parker, A. [1 ]
Lal, R. [1 ]
Olmos, D. [1 ]
Mollenhauer, M. [2 ]
Walz, A. [2 ]
de Bono, J. S. [1 ]
机构
[1] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England
[2] Nycomed GmbH, Exploratory Clin Dev, Constance, Germany
来源
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词
D O I
10.1016/S1359-6349(08)72327-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:123 / 124
页数:2
相关论文
共 50 条
[21]   Lung cancer: First-in-man phase I trial with lorlatinib [J].
Romero D. .
Nature Reviews Clinical Oncology, 2018, 15 (1) :7-7
[22]   Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies [J].
Ramalingam, Suresh S. ;
Parise, Robert A. ;
Ramananthan, Ramesh K. ;
Lagattuta, Theodore F. ;
Musguire, Lori A. ;
Stoller, Ronald G. ;
Potter, Douglas M. ;
Argiris, Athanassios E. ;
Zwiebel, James A. ;
Egorin, Merrill J. ;
Belani, Chandra P. .
CLINICAL CANCER RESEARCH, 2007, 13 (12) :3605-3610
[23]   First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors [J].
Yap, Timothy A. ;
Yan, Li ;
Patnaik, Amita ;
Fearen, Ivy ;
Olmos, David ;
Papadopoulos, Kyriakos ;
Baird, Richard D. ;
Delgado, Liliana ;
Taylor, Adekemi ;
Lupinacci, Lisa ;
Riisnaes, Ruth ;
Pope, Lorna L. ;
Heaton, Simon P. ;
Thomas, George ;
Garrett, Michelle D. ;
Sullivan, Daniel M. ;
de Bono, Johann S. ;
Tolcher, Anthony W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) :4688-4695
[24]   A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors [J].
Brunetto, A. T. ;
Ang, J. E. ;
Lal, R. ;
Olmos, D. ;
Frentzas, S. ;
Mais, A. ;
Hauns, B. ;
Mollenhauer, M. ;
Lahu, G. ;
de Bono, J. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[25]   A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) [J].
Kelly, W ;
O'Connor, O ;
Richon, VM ;
Tong, W ;
Rao, TD ;
Chiao, J ;
O'Brien, JP ;
Rifkid, RA ;
Marks, PA ;
Scher, HI .
EUROPEAN JOURNAL OF CANCER, 2002, 38 :S88-S88
[26]   Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors [J].
Siu, L. L. ;
Carducci, M. ;
Chen, E. X. ;
Maclean, M. ;
Pili, R. ;
King, S. ;
Patterson, T. ;
Li, Z. ;
Kalita, A. ;
Reid, G. K. .
EJC SUPPLEMENTS, 2006, 4 (12) :94-95
[27]   Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors [J].
Wainberg, Zev A. ;
de Bono, Johann S. ;
Mina, Lida ;
Sachdev, Jasgit ;
Byers, Lauren Averett ;
Chugh, Rashmi ;
Zhang, Charlie ;
Henshaw, Joshua W. ;
Dorr, Andrew ;
Glaspy, John ;
Ramanathan, Ramesh .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[28]   Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor [J].
Donovan, EA ;
Ryan, Q ;
Acharya, M ;
Chung, E ;
Trepel, J ;
Maynard, K ;
Sausville, E ;
Murgo, A ;
Melillo, G ;
Conley, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :215S-215S
[29]   Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma [J].
Watanabe, Takashi ;
Kato, Harumi ;
Kobayashi, Yukio ;
Yamasaki, Satoshi ;
Morita-Hoshi, Yuriko ;
Yokoyama, Hiroki ;
Morishima, Yasuo ;
Ricker, Justin L. ;
Otsuki, Tetsuya ;
Miyagi-Maesima, Akiko ;
Matsuno, Yoshihiro ;
Tobinai, Kensei .
CANCER SCIENCE, 2010, 101 (01) :196-200
[30]   Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers [J].
Piekarz, R. ;
Luchenko, V. ;
Draper, D. ;
Wright, J. J. ;
Figg, W. D. ;
Fojo, A. T. ;
Bates, S. E. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)